Paradigm Biopharmaceuticals Limited (PBIGF)
| Market Cap | 68.80M -30.3% |
| Revenue (ttm) | 5.64K -49.4% |
| Net Income | -24.07M |
| EPS | -0.07 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 200 |
| Open | 0.1241 |
| Previous Close | 0.1237 |
| Day's Range | 0.1241 - 0.1241 |
| 52-Week Range | 0.1009 - 0.3468 |
| Beta | -0.02 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 28, 2026 |
About PBIGF
Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. Its lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is headquartered in Melbourne, Australia. [Read more]
News
Australia's Paradigm Biopharmaceuticals says phase 2 trial in osteoarthritis shows signs of disease modification at 6-month follow-up
Top-line phase 2 trial data shows disease modifying potential and pain reduction Top-line phase 2 trial data shows disease modifying potential and pain reduction
PARADIGM BIOPHARMACEUTICALS LTD. APPOINTS MARCO POLIZZI as CHIEF EXECUTIVE OFFICER
Polizzi Possesses More Than 30 Years of Experience in the Pharmaceutical Industry. NEW YORK , June 27, 2022 /PRNewswire/ -- Paradigm Biopharmaceuticals Ltd (ASX: PAR) ("Paradigm" or "the Company"), a ...
PARADIGM BIOPHARMACEUTICALS SPOTLIGHTS POTENTIAL BREAKTHROUGH OSTEOARTHRITIS TREATMENT AT BIOLOGICAL ASSOCIATION 3RD ANNUAL SUMMIT
Global Clinical Head Dr. Mukesh Ahuja Presented, "Injectable Pentosan Polysulfate Sodium for Knee Osteoarthritis: A Potential Disease-Modifying Osteoarthritis Drug." NEW YORK , May 24, 2022 /PRNewswir...
Paradigm Biopharmaceuticals Retains Rubenstein Public Relations as Agency of Record
Global Biopharmaceutical Company Hires Leading PR Firm as it Expands Their U.S. Operations NEW YORK, April 19, 2022 /PRNewswire/ -- Paradigm Biopharmaceuticals ("Paradigm"), a global biopharmaceutica...
FDA Grants Fast Track Designation for Paradigm Biopharmaceuticals Phase III Osteoarthritis Program
Approval demonstrates the potential of Zilosul™ to address an unmet medical need in OA which effects more than 72 million people in the US, EU5, and Canada KEY HIGHLIGHTS FDA Fast Track Designation fo...
Paradigm Biopharmaceuticals Initiates a Phase 3 Clinical Trial in Knee Osteoarthritis Across the U.S
The company plans an estimated 56 clinical trial locations nationwide MELBOURNE, Australia, March 17, 2022 /PRNewswire/ -- Paradigm Biopharmaceuticals (ASX: PAR) a global biopharmaceutical company dri...